Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On March 31, 2026 the Compensation Committee approved restricted stock awards for four new non‑executive employees, covering up to 8,400 restricted shares. One‑third vests each year, with full vesting on the third anniversary, subject to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – ABEO
In the Apr 6 session, ABEO declined 1.24%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | New treatment center | Positive | +5.2% | Added NewYork-Presbyterian/Columbia as fifth Qualified Treatment Center for ZEVASKYN. |
| Mar 17 | Full-year results | Positive | -3.8% | Reported 2025 financials with PRV sale-driven profit and ZEVASKYN launch update. |
| Mar 09 | Launch update | Positive | +6.4% | Highlighted building commercial momentum and broad coverage for ZEVASKYN launch. |
| Mar 03 | Earnings date & conference | Neutral | -2.4% | Announced timing of Q4/2025 call and Leerink conference participation. |
| Feb 09 | Inducement grants | Neutral | +0.0% | Granted restricted stock inducement awards to new non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Commercial and business updates around ZEVASKYN have coincided with positive moves, while the earnings release with large one-time items saw a negative reaction, suggesting sensitivity to financial detail despite operational progress.
Over recent months, Abeona has transitioned into a commercial-stage gene therapy company with FDA-approved ZEVASKYN, expanding access via multiple Qualified Treatment Centers and broad payer and Medicaid coverage. Business updates on launch momentum (Mar 9) and new treatment centers (Apr 2) coincided with positive price reactions. In contrast, full-year 2025 results on Mar 17, despite profitability driven by a Priority Review Voucher sale, saw a share decline. The current inducement grant mirrors a prior February HR-related grant that had no material price impact.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On March 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts:
Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
